Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and clinical activity of pembrolizumab immunotherapy and multi-organ site ablative stereotactic body radiotherapy (iMOSART) in patients with advanced solid tumors.
Authors
Jeffrey Lemons
University of Chicago, Chicago, IL
Jeffrey Lemons, Jason J. Luke, Theodore Karrison, Sean Pitroda, James Melotek, Yuanyuan Zha, Hania A Al-Hallaq, Ainhoa Arina, Linda A. Janisch, Paul J Chang, Jyoti D. Patel, Gini F. Fleming, John William Moroney, Manish Sharma, Julia R. White, Mark J. Ratain, Thomas Gajewski, Ralph R. Weichselbaum, Steven J. Chmura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Novel Clinical Trial Designs
Clinical Trial Registration Number
NCT02608385
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 20)
DOI
10.1200/JCO.2018.36.5_suppl.20
Abstract #
20
Poster Bd #
A1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
First Author: Mark Charles Korpics
Poster
2022 ASCO Annual Meeting
Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.
First Author: Olivier Rixe
Poster
2018 ASCO Annual Meeting
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
First Author: Andreea Varga
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang